Abstract 502P
Background
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the standard therapy for advanced non-small cell lung cancer (NSCLC) with common EGFR mutations. However, the efficacy of EGFR-TKIs in patients with uncommon EGFR mutations remains unclear.
Methods
We retrospectively surveyed a consecutive database of patients with NSCLC with EGFR mutations. We analyzed the data of patients with NSCLC with uncommon mutations, including single or compound mutations, who were treated with EGFR-TKIs between May 2016 and October 2018.
Results
Data from 543 patients were collected from five institutions, among whom 23 had EGFR uncommon mutations. Twenty-one patients who were treated with any EGFR-TKIs were analyzed in this study, 18 of whom were treated with EGFR-TKIs as first-line therapy (gefitinib 5, erlotinib 3, afatinib 10 patients). In contrast, three patients underwent cytotoxic chemotherapy as first-line therapy and were treated with EGFR-TKIs as second- and third-line therapy (gefitinib 1, erlotinib 1, afatinib 1 patient). According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was 56%, and the disease control rate was 78%. The median progression-free survival (PFS) was 14.0 months in all patients with uncommon mutations. The median PFS of patients who were treated with first and second generation EGFR-TKIs were 14.0 months (n = 10) and 7.3 months (n = 11), respectively. Moreover, the PFS of patients with the G719X mutation (n = 12, median PFS: 32.9 months) was longer than that of patients with the L861Q mutation (n = 4, median PFS: 11.1) and compound mutations (n = 4, median PFS 7.3 months).
Conclusions
First and second generation EGFR-TKIs are effective treatments for patients with NSCLC with uncommon mutations. Notably, a greater favorable response was observed in patients with G719X mutations than those with L861Q and compound mutations.
Clinical trial identification
UMIN000028989.
Editorial acknowledgement
Legal entity responsible for the study
Fumio Imamura.
Funding
AstraZeneca.
Disclosure
F. Imamura: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract